Psurotin A inhibits osteoclastogenesis and prevents ovariectomized-induced bone loss by suppressing reactive oxygen species.

Kai Chen¹, #, Pengcheng Qiu², ³, #, Yu Yuan¹, ⁴, Lin Zheng², ³, Jianbo He¹, ⁵, Chao Wang¹, Qiang Guo¹, ⁶, Jacob Kenny¹, Qian Liu⁷, ⁸, ⁹, Jingmin Zhao⁷, ⁸, ⁹, Junhao Chen¹, Jennifer Tickner¹, Shunwu Fan², ³, Xianfeng Lin², ³, *, Jiake Xu¹, *

¹ School of Biomedical Sciences, University of Western Australia, Perth, WA 6009, Australia.
² Department of Orthopedic Surgery, Sir Run Run Shaw Hospital, Medical College of Zhejiang University, Hangzhou, Zhejiang 310000, China
³ Key Laboratory of Musculoskeletal System Degeneration and Regeneration Translational Research of Zhejiang Province, Hangzhou, Zhejiang 310000, China
⁴ School of Physical Education and Sports Science, South China Normal University, Guangzhou, Guangdong 510631, China
⁵ Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510000, China
⁶ Department of Spine Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
⁷ Research Centre for Regenerative Medicine, Guangxi Medical University, Nanning, Guangxi 530021, China
⁸ Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Nanning, Guangxi 530021, China
⁹ International Joint Laboratory on Regeneration of Bone and Soft Tissues, Guangxi Medical University, Nanning, Guangxi 530021, China

#Co-first authors: Kai Chen and Pengcheng Qiu contributed equally to this work.

*Corresponding authors: 1. Jiake Xu Email: jiake.xu@uwa.edu.au; Phone: +61 8 6457 2739
2. Xianfeng Lin Email: xianfeng.lin@zju.edu.cn; Phone: +86 571 8600 2194
Abstract

**Rationale:** Growing evidence indicates that intracellular reactive oxygen species (ROS) accumulation is a critical factor in the development of osteoporosis by triggering osteoclast formation and function. Pseurotin A (Pse) is a secondary metabolite isolated from Aspergillus fumigatus with antioxidant properties, recently shown to exhibit with a wide range of potential therapeutic applications. However, its effects on osteoporosis remain unknown. This study aimed to explore whether Pse, by suppressing ROS levels, is able to inhibit osteoclastogenesis and prevent the bone loss induced by estrogen-deficiency in ovariectomized (OVX) mice.

**Methods:** The effects of Pse on receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL)-induced osteoclastogenesis and bone resorptive function were examined by tartrate resistant acid phosphatase (TRAcP) staining and hydroxyapatite resorption assay. 2',7'-dichlorodihydrofluorescein diacetate (H₂DCFDA) was used to detect intracellular ROS production in vitro. Western blot assay was used to identify proteins associated with ROS generation and scavenging as well as ROS-mediated signaling cascades including mitogen-activated protein kinases (MAPKs), NF-κB pathways, and nuclear factor of activated T cells 1 (NFATc1) activation. The expression of osteoclast-specific genes was assessed by qPCR. The in vivo potential of Pse was determined using an OVX mouse model administered with Pse or vehicle for 6 weeks. In vivo ROS production was assessed by intravenous injection of dihydroethidium (DHE) into OVX mice 24h prior to killing. After sacrifice, the bone samples were analyzed using μCT and histomorphometry to determine bone volume, osteoclast activity, and ROS level in vivo.

**Results:** Pse was demonstrated to inhibit osteoclastogenesis and bone resorptive function in vitro, as well as the downregulation of osteoclast-specific genes including *Acp5* (encoding TRAcP), *Ctsk* (encoding cathepsin K), and *Mmp9* (encoding matrix metalloproteinase 9). Mechanistically, Pse suppressed intracellular ROS level by inhibiting RANKL-induced ROS production and enhancing ROS scavenging enzymes, subsequently suppressing MAPK pathway activation (ERK, P38, and JNK) and NF-κB pathways, as well as inhibiting NFATc1 signaling. μCT and histological results indicated that OVX resulted in significant bone loss, with dramatically increased numbers of osteoclasts on the bone surface as well as increased ROS levels in the bone marrow microenvironment; whereas Pse supplementation was capable of effectively preventing these OVX-induced changes.

**Conclusion:** Pse was demonstrated for the first time as a novel alternative therapy for osteoclast-related bone disease such as osteoporosis through suppressing ROS levels.

**Key words:** Pseurotin A, reactive oxygen species, osteoclast, osteoporosis
Introduction

The maintenance of bone homeostasis is achieved by the delicate balance between osteoblastic bone formation and osteoclastic bone resorption. Uncoordinated activities of osteoblasts and osteoclasts can result in various perturbations in skeletal structure and function thus leading to bone diseases such as Paget’s disease of bone and osteoporosis [1, 2]. Estrogen deficiency-induced bone loss, due to enhanced osteoclast activity, plays an essential role in osteoporosis in postmenopausal women, leading to fragility fractures that are often associated with life-threatening mortality and morbidity, as well as massive economic cost to both individuals and society [3].

Osteoclasts are large multinucleated cells which are derived from hematopoietic progenitors. The formation of mature osteoclasts is dependent on several crucial factors, including macrophage-colony stimulating factor (M-CSF) and receptor activator of nuclear factor kappa B (NF-κB) ligand (RANKL). Osteoclast precursor cells undergo survival and proliferation in response to the binding of M-CSF to its receptor c-Fms [4]. RANKL is an indispensable and sufficient factor for osteoclastogenesis, via its action on RANK receptor [5]. After stimulation with RANKL, recruitment of TNF receptor-associated factor 6 (TRAF6) is induced to activate multiple downstream targets including mitogen-activated protein kinases (MAPKs) and NF-κB pathways, leading to activation of c-Fos and nuclear factor of activated T cells 1 (NFATc1) [6-8]. These signaling cascades enable the expression of genes that typify the osteoclast lineage including Acp5 (encoding tartrate-resistant acid phosphatase [TRAcP]), Ctsk (encoding cathepsin K), and Mmp9 (encoding matrix metalloproteinase 9), thus eventually leading to the formation of mature osteoclasts [6].

Growing evidence also indicates that intracellular reactive oxygen species (ROS) play a crucial role during osteoclast formation and bone resorption [9-11]. ROS are endogenously produced in osteoclast precursors following stimulation with RANKL, via a signaling cascade involving TRAF6, Rac1, and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 1 (Nox1)[9]. Application of oxidant scavenger like N-acetylcysteine (NAC) or Nox inhibitor such as diphenylene iodonium (DPI), was found to inhibit osteoclastogenesis by suppressing RANKL-mediated ROS production [9], indicating ROS are required for osteoclast differentiation. Cellular protective mechanisms against oxidative stressors also include a variety of cytoprotective or antioxidant enzymes, such as heme oxygenase-1 (HO-1), catalase, glutathione reductase (GSR), NAD(P)H: quinone reductase (NQO1), and γ-glutamylcysteine synthetase (GCS) [12, 13]. Antioxidants were shown to attenuate osteoclast formation and bone resorption by enhancing expression of the cytoprotective enzymes [14, 15]. The downstream targets of ROS in RANKL-mediated signaling still remain unclear; however, a higher level of oxidative stress was suggested to promote osteoclast formation and function through the activation of NF-κB and MAPKs [13, 16]. In addition, ROS production is highly involved in bone remodeling and bone homeostasis by promoting bone resorption [16, 17]. Estrogen deficiency-induced osteoporosis is associated with a higher level of oxidative stress and can be prevented by increasing oxidant defense [18-20]. Therefore, these findings might provide a rationale for using ROS scavenging as a potential strategy for the treatment of osteoporosis.

Pseurotin A (Pse) is a bioactive secondary metabolite originally isolated from Pseudoeurotium ovalis [21] and later also from several species of Aspergillus [22-24]. A single hybrid polyketide synthase/non-ribosomal peptide synthetase (PKS/NRPS) [25] gene and the rtfA gene [26] are
associated with the biosynthesis of Pse in Aspergillus fumigatus. The expression of Pse is also induced in response to hypoxia [27]. So far, Pse has demonstrated potential therapeutic applications due to its immunosuppressive activity [28], antibacterial activity [29], nematicidal activity [30], antiparasitic as well as anticancer activity [22]. Furthermore, Pse was found to have antioxidant and radical-scavenging activity, as demonstrated by its ability to scavenge the DPPH (2, 2-diphenyl-1-picrylhydrazyl) radical [31].

Given the significant role of ROS on osteoclast formation and function, the potential antioxidant activity as well as other various potential therapeutic applications of Pse, we hypothesized that Pse might inhibit osteoclasts and thus prevent osteoclast-related osteoporosis. In the present study, we assessed the therapeutic effects of Pse on RANKL-induced osteoclastogenesis in vitro and ovariectomized (OVX)-induced osteoporosis mouse models in vivo, with a focus on determining the antioxidant capacity of Pse in vitro and in vivo and elucidated its underlying mechanisms.

Materials and Methods

Materials and reagents

Pse, obtained from SHANGHAI ZZBIO CO., LTD (Shanghai, China), was dissolved in Dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Sydney, NSW, Australia) at a concentration of 100 mM and further diluted to working concentrations with culture medium. DMSO of the same dilution was used as vehicle control. Alpha modified Minimal Essential Medium (α-MEM) and fetal bovine serum (FBS) were purchased from Thermo Fisher Scientific (Scoresby, VIC, Australia). MTS assay kit and luciferase analysis system were purchased from Promega (Sydney, NSW, Australia). Primary antibodies for TRAF6, GSR, IκB-α, β-actin, phospho-ERK, ERK, phospho-P38, P38, NFATc1, Integrin αV, cathepsin K, and V-ATPase-d2 were purchased from Santa Cruz Biotechnology (Dallas, CA, USA). Primary antibodies for HO-1, catalase, phospho-JNK, JNK, and Active Rac1 Detection Kit were purchased from Cell Signaling Technology (Danvers, MA, USA). Primary antibody for anti-vinculin was purchased from Sigma-Aldrich (Sydney, NSW, Australia). Recombinant M-CSF was purchased from R&D Systems (Minneapolis, MN, USA). Recombinant Glutathione S-transferase (GST)-rRANKL protein was expressed and purified as previously described[32]. Rhodamine Phalloidin, ProLong Gold Antifade Mountant, and 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) were obtained from Thermo Fisher Scientific (Scoresby, VIC, Australia) and 4,6-diamidino-2-phenylindole (DAPI) was purchased from Santa Cruz Biotechnology (Santa Cruz, Dallas, CA, USA). Dihydroethidium (DHE) was purchased from ApexBio (Boston, MA, USA).

In vitro osteoclastogenesis assay

Fresh bone marrow macrophages (BMMs) from C57BL/6J mice were isolated using methods approved by the University of Western Australia Animal Ethics Committee (RA/3/100/1244) as described [16]. In brief, bone marrow was flushed from the femur and tibia and then cultured in α-MEM/10% FBS/Penicillin/streptomycin (complete αMEM). To obtain pure BMMs, non-adherent cells were then collected and cultured in complete αMEM containing M-CSF (50 ng/mL). After a further 3 days in culture, the attached cells were used for experimental purposes. BMMs were plated in 96-well plates at a density of 6 × 10³ cell/well overnight. The following
day, cells were stimulated with M-CSF and GST-rRANKL (50 ng/mL) in the presence or absence of increasing concentrations of Pse (2.5, 5, 7.5, 10 µM). Medium was replaced every 2 days until osteoclasts formed. The cells were then fixed with 2.5% glutaraldehyde solution for 10 min and stained for tartrate resistant acid phosphatase (TRAcP) enzymatic activity using a leucocyte acid phosphatase staining kit (Sigma-Aldrich, Sydney, NSW, Australia). Cells with more than 3 nuclei were counted as osteoclasts.

Cytotoxicity assay

BMMs were seeded in 96-well plates at a density of 6 × 10³ cells/well and incubated overnight to allow adherence. Cells were then treated with different concentrations of Pse (0, 2.5, 5, 7.5, 10 µM) for 48 h. At the end of the experiment, MTS solution (20 µL/well) was added and the plate was incubated for an additional 2 h. The optical density (OD) was measured by spectrophotometric absorbance at 490nm using a microplate reader (BMG LABTECH, Ortenberg, Germany).

Staining for podosome belts

To visualize podosome belts, BMMs were seeded onto FBS-coated coverslips (5-mm diameter) in 96-well plates and were induced to form osteoclasts, as described above, in the presence of Pse (0, 5, 10 µM). Osteoclasts were then fixed 4% paraformaldehyde (PFA) for 10 min, permeabilized with 0.1% (v/v) Triton X-100 for 10 min and blocked with 3% BSA in PBS for 1 h. Cells were then incubated with mouse monoclonal anti-vinculin (1:200) at 4 °C overnight, followed by washing in PBS and incubation with a fluorescent secondary anti-mouse antibody (Alexa Fluor 488, green). F-actin was stained with Rhodamine Phalloidin in the dark for 1 h. After that, cells were washed with PBS, stained with DAPI for 10 min, washed again, and mounted in ProLong Gold Antifade Mountant prior to visualization using a NIKON A1Si confocal microscope (Nikon Corporation, Minato, Tokyo, Japan).

Quantitative real-time PCR

BMMs were cultured in 6-well plates (1 × 10⁵ cells/well) and stimulated with GST-rRANKL and M-CSF in the presence of Pse (0, 5, 10 µM) until osteoclasts formed. Total RNA was isolated from the cells using Trizol reagent (Life Technologies, Sydney, Australia) and single stranded cDNA was prepared from 1 μg of total RNA template using moloney murine leukemia virus (MMLV) reverse transcriptase with oligo-dT primer (Promega, Sydney, NSW, Australia). For relative quantitative real-time PCR (qPCR), SYBR Green PCR MasterMix (Thermo Fisher Scientific, Scoresby, VIC, Australia) was used. The cycling parameters for PCR were set as follows: 94 °C for 5 min, followed by 30 cycles of 94 °C for 40 s, 60 °C for 40 s, and 72 °C for 40 s, followed by an elongation step of 5 min at 72 °C. The specific primers used are as following: Ctsk (forward: 5′-GGGAGAAAAACCTGAGACCTGA AGC-3′; reverse: 5′-ATTCTGGGACACTCAGAGC-3′), Acp5 (forward: 5′-TGTTGCCATCTTTATG CT-3′; reverse: 5′-GTCATTCTTCTTGGGCTT3′), Atp6v0d2 (Forward: 5′-GTGAGACCTTGGAAGACCTGGAGACCTGAA-3′; Reverse: 5′-GAGAAATGTGCTCAGGGGCTT3′), Mmp9 (Forward: 5′-CAGCTGGCTGGAGGAGGGCTT3′), Mmp9 (Forward: 5′-TTGAAACCTGACACGCACCCAGA-3′), Nfatc1 (Forward: 5′-CAACGCCCTGACCACCGGCTGAA-3′; Reverse: 5′-GGCTGGCTCCGTCTTCGCTGAG-3′), C-fos (Forward: 5′-GCAGCAACTGAGGAGACAGC-3′; Reverse: 5′-TTGAAACCCGAGAACATCT-3′), Hmbs (Forward: 5′-
AAGGGCTTTTCTGAGGCACC -3'; Reverse: 5'—AGTTGCCCATCTTTTACACTG- 3'), Hprt1 (Forward: 5'—TCAGTCAACGGGGGACATAAA-3'; Reverse: 5'-GGGGCTGTACTGCTTAACCAG -3'). The qPCR procedure was performed on a ViiA 7 Real-time PCR machine (Applied Biosystems, Warrington, Cheshire, UK). Target gene expression levels were normalized to average expression of Hprt1 and Hmbs.

**Hydroxyapatite resorption assay**

To determine whether Pse affects osteoclast function, hydroxyapatite resorption assay was performed as described previously [15, 33, 34]. BMMs were plated in 6-well collagen-coated plates (Corning Inc., Corning, NY, USA) in complete αMEM with M-CSF at a density of 1 x 105 cells/well. The following day cells were stimulated with 50 ng/mL GST-RANKL until osteoclasts began to form. Cells were then gently detached using cell dissociation solution (Sigma-Aldrich, Sydney, NSW, Australia) and an equal number of cells were seeded into each well of hydroxyapatite-coated plate (Corning Inc., Corning, NY, USA). Cells were treated with Pse at increasing concentrations (0, 5, 10 µM) in complete αMEM containing 50 ng/mL GST-rRANKL and M-CSF. After 48 h incubation, half of the wells for each group were washed with 10% bleach solution to remove cells and the images of hydroxyapatite resorption areas were captured using a Nikon microscope (Nikon Corporation, Minato, Tokyo, Japan) and quantified using Image J software (NIH, Bethesda, Maryland, USA). The remaining wells were fixed and stained for TRAcP activity as above to count the number of osteoclasts. The resorbed area per well and the percentage of resorbed area per osteoclast were used to quantify the osteoclast activity.

**Detection of intracellular ROS production**

The intracellular production of ROS was measured as described previously [9]. Briefly, after stimulation with GST-rRANKL (50 ng/mL) in the absence or presence of Pse at stated concentrations (5, 10 µM), BMMs were then incubated in Hank's balanced salt solution containing 5 mM H2DCFDA for 1 h. Upon oxidation, the nonfluorescent H2DCFDA will be converted to the highly fluorescent 2',7'-dichlorofluorescein (DCF). The fluorescence of DCF was measured at an excitation wavelength of 488 nm and an emission wavelength of 515–540 nm using a NIKON A1Si confocal microscope. Cells images were also captured by digital interference contrast (DIC). The mean fluorescence intensity for each cell and the number of ROS-positive cells per field were analyzed using Image J software.

**Luciferase reporter assays of NF-κB or NFATc1**

RAW264.7 cells (ATCC, Manassas, Virginia, USA), stably transfected with an NF-κB responsive luciferase construct [35] and an NFATc1 responsive luciferase reporter construct [36], were seeded in 48-well plates at a density of 1.5 x 105 cells/well or 5 x 104 cells/ well overnight, respectively. Cells were then pre-treated with Pse for 1 h and stimulated with GST-rRANKL (50 ng/mL) for 6 h and 24 h respectively. At the end of the time points, cells were lysed and luciferase activity was measured using the luciferase reporter assay kit (Promega, Sydney, NSW, Australia) and a luminescence reader (BMG LABTECH, Ortenberg, Germany).

**Western blot Assay**
BMM cells were seeded in 6-well plates (1 × 10^5 cells/well) and stimulated with GST-rRANKL and M-CSF in the presence or absence of Pse (10 µM) for the stated times. Cells were lysed in radioimmunoprecipitation (RIPA) lysis buffer to harvest protein. For GTP-Rac1 detection, cell lysates were collected and incubated with GST-Human PAK1-PBD fusion protein that binds to GTP-bound Rac1 using Active Rac1 Detection Kit (Cell Signaling Technology, Danvers, MA, USA). Protein was separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane (GE Healthcare, Silverwater, Australia). Non-specific binding was blocked by incubation in 5% skim milk powder and the membrane was then incubated with primary antibodies (1:1000) with gentle shaking overnight at 4 °C. The next day, membranes were washed and incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies at room temperature for 1 h. Antibodies were detected with enhanced chemiluminescence substrate (PerkinElmer, Waltham, MA, USA). Images were acquired on an Image-quant LAS 4000 (GE Healthcare, Silverwater, NSW, Australia) and analyzed by ImageJ software.

**Ovariectomized (OVX)-induced osteoporosis mouse model**

All in vivo experimental procedures were approved by the Institutional Animal Ethics Committee of Sir Run Run Shaw Hospital. Eighteen C57BL/6J mice (females; 18.6 ± 1.4 g, 11 weeks old) were supplied by Animal Experiment Center of Sir Run Run Shaw Hospital (Hangzhou, Zhejiang, China). All mice were randomly divided into three groups: sham group (n=6), OVX group (n=6), and OVX+Pse (5 mg/kg) group (n=6). Bilateral ovariectomy was carried out to induce osteoporosis under chloral hydrate anesthesia for the mice in OVX group and OVX+Pse group, a sham procedure in which the ovaries were only exteriorized but not resected was performed for the mice in sham group. All mice had a 1-week-recovery after operations, then the mice in the OVX +Pse group were administrated an intraperitoneal injection of Pse at 5 mg/kg every 2 days for 6 weeks. The mice in the sham and OVX groups were intraperitoneally injected with vehicle (1% DMSO in PBS) as a control. ROS production in vivo was determined using DHE following previously described protocols with modifications [37]. In brief, 24h before killing, each mouse received a 200-µL intravenous injection of DHE at 25 mg/kg.

**µCT scanning and analysis**

After sacrifice, the femurs were collected and fixed in 10% neutral buffered formalin for 24 h and the excess soft tissue was removed. Left femurs were scanned using a SkyScan 1176 microCT instrument (Bruker microCT, Kontich, Belgium) using the following settings: source voltage, 50 kV; source current, 500 µA; AI 0.5 mm filter; pixel size 9 µm; rotation step, 0.4 degree. The images were then reconstructed with NRecon software (Bruker microCT, Kontich, Belgium) using the following settings: ring artefact correction, 7; smoothing, 2; beam hardening correction, 40%. A refined volume of interest was generated 0.5mm above the growth plate of the distal femur and 1 mm in height. The trabecular bone region of interest (ROI) within this volume was manually defined and bone parameters within this ROI were all determined using a constant threshold (50 ~ 255) for binarization of the trabecular bone. The following parameters, including bone volume per tissue volume (BV/TV), trabecular number (Tb.N), connectivity density (Conn.Dn), and trabecular thickness (Tb.Th), were analyzed by the program CTAn (Bruker microCT, Kontich, Belgium). Cortical bone analysis was performed in the mid shaft (4 mm below the growth plate with a height of 1 mm) and a constant threshold (100~ 255) for binarization was used.
Bone histomorphometry analysis

Following microCT analysis, femurs were decalcified in 14% EDTA (Sigma-Aldrich, Sydney, NSW, Australia) at 37 °C for 7 days, and then embedded into paraffin for sectioning. Hematoxylin and eosin (H&E) staining and TRAcP activity staining were performed. Section images were acquired using Aperio Scanscope (Mt Waverley, VIC, Australia), and bone histomorphometric analyses were performed using BIOQUANT OSTEO software (Bioquant Image Analysis Corporation, Nashville, TN, USA).

For in vivo ROS fluorescence detection, cryosections of bone tissue were prepared as previously described [38]. Fresh bone tissues were dissected, cleaned and immediately fixed in 4% paraformaldehyde (Sigma-Aldrich, Sydney, NS, Australia) solution at 4 °C for 4 h. Next, decalcification was carried out with 0.5 M EDTA overnight at 4 °C under constant rotation, after which the EDTA was exchanged for cryoprotective solution composed of 20% sucrose and 2% polyvinylpyrrolidone (PVP) (Sigma-Aldrich, Sydney, NSW, Australia) for 24 h. Finally, the resultant tissues were embedded and frozen in 8% gelatin in the presence of 20% sucrose and 2% PVP. 5 μm sections were generated and air-dried at room temperature prior to permeabilization for 10 min in 0.3% Triton X-100 (Sigma-Aldrich, Sydney, NSW, Australia). Nuclei were stained with DAPI for 30 min. After washing with PBS, sections were mounted and coverslips were sealed with nail polish. A Nikon A1Si confocal microscope (Nikon Corporation, Minato, Tokyo, Japan) was used for imaging. The fluorescence intensity of 6 random areas of each group were quantified and analyzed using NIS-Elements software (Nikon Corporation, Minato, Tokyo, Japan).

Statistical analysis

Each experiment was repeated at least three times. All quantitative data are presented as mean ± standard deviation (SD). Statistical significance was determined by Student’s t test. A p-value of less than 0.05 was considered to be significant.

Results

Pse suppresses RANKL-induced osteoclastogenesis in vitro

The chemical structure and formula of Pse are shown in Figure 1A. To identify the effect of Pse on osteoclastogenesis, BMMs were seeded in 96-well plates and treated with both M-CSF and RANKL in the presence or absence of various concentrations of Pse as indicated. The purity of isolated precursor BMMs was approximately 99%, as assessed by flow cytometry for CD11b (Figure S1). Numerous TRAcP-positive multinucleated osteoclasts formed in the RANKL-induced control group (without Pse), whereas increasing concentrations of Pse exerted a dose-dependent inhibition on osteoclastogenesis (Figure 1B and C). To determine any potential cytotoxicity of Pse on BMMs, MTS assay was performed to assess cell viability. Pse was found to have no effect on BMM proliferation over the concentrations used in this study (Figure 1D). To examine which stage of osteoclastogenesis was affected, cells were treated with 10 μM Pse at indicated time phases (Figure 1E). Pse was found to predominantly exert its suppressive effect
during mid-late stage (Day 3-6) of osteoclast differentiation, rather than early stage (Day 1-3) (Figure 1F).

**Pse affects podosome belt formation and inhibits osteoclast-specific gene expression**

Cells were co-stained with rhodamine-phalloidin and anti-vinculin to visualize podosome belt formation and morphological changes in cells treated with or without Pse. As shown in Figure 2A, after RANKL stimulation well-defined podosome belts with intact nuclei formed in mature osteoclasts. In contrast, smaller osteoclasts with fewer nuclei were observed after Pse treatment (5, 10 μM) (Figure 2B and C).

Several osteoclast-specific genes, including c-fos, Nfatc1, Ctsk, Acp5, Atp6v0d2, and Mmp9 are upregulated in BMMs when osteoclast differentiation is induced. We examined these genes at mRNA level using quantitative PCR to observe how Pse affected osteoclast specific gene expression and found that their expression was inhibited during RANKL-induced osteoclastogenesis following the addition of Pse (Figure 2D-I). Collectively, these results further confirmed that Pse suppressed the expression of osteoclast-specific genes and thus osteoclastogenesis in vitro.

**Pse inhibits osteoclast resorptive function**

We next determined whether Pse has an effect on osteoclast resorptive activity using hydroxyapatite-coated plates. A reduction in the number of osteoclasts and the resorption area were observed at both Pse concentrations (5, 10 μM) (Figure 3A and B). In addition, following normalization of resorption area to the number of osteoclasts, a dose-dependent inhibitory effect on osteoclast resorptive function was observed as compared to the control group (Figure 3C).

**Pse reduces RANKL-induced intracellular ROS level in BMMs**

To investigate whether RANKL-induced ROS production during osteoclast differentiation was reduced by Pse, ROS levels were visualized using a cell-permeable, oxidation-sensitive dye H$_2$DCFDA. ROS oxidation of this dye was detected as a fluorescent signal derived from the oxidation product DCF using confocal microscopy. The intensity of DCF fluorescence was significantly decreased in a dose-dependent manner in BMMs when stimulated with M-CSF and RANKL in the presence of Pse (5, 10 μM) (Figure 4 A-C). Therefore, our results indicated that Pse inhibited osteoclast formation and activity via scavenging ROS.

**Pse suppresses intracellular ROS level by down-regulating the TRAF6/Rac1/Nox1 signaling cascade as well as enhancing expression of antioxidant enzymes**

To determine whether Pse affects ROS generation, the activation level of Nox1, known as a major contributing factor in ROS generation [9, 39], was investigated using western blot. BMMs were incubated with RANKL for 2 days in the absence or presence of Pse at different concentrations as indicated. Nox1 expression was significantly up-regulated by RANKL, but dose-dependently inhibited by Pse at the concentrations of 2.5-10 μM (Figure 4 D and F). TRAF6 and GTP-Rac1 are required for the Nox1 activation, we therefore examined whether Pse inhibited Nox1 by attenuating TRAF6 and GTP-Rac1. Adaptor protein TRAF6 expression was augmented by RANKL and showed a trend of down-regulation at high concentrations (10 μM),
which was not significant (Figure 4 D and E). GTP-bound Rac1 is a cytosolic component of Nox1 and is responsible for Nox1 activation. As shown in Figure 1G and H, GTP-Rac1 activation was significantly enhanced after 5 min and 15 min of RANKL stimulation but was attenuated by Pse treatment in a dose-dependent manner. Next, to examine whether Pse is able to scavenge ROS by up-regulating antioxidant enzymes, the expression of antioxidant enzymes including HO-1, catalase, and GSR were examined. As shown in Figure 1 I and J, the expression of HO-1 was reduced by RANKL stimulation but was recovered and enhanced dose-dependently by Pse treatment. Similarly, Pse also enhanced the expression levels of catalase and GSR. Taken together, these data mechanistically suggest that Pse suppresses RANKL-induced intracellular ROS level via inhibition of ROS generation as well as the enhancement of ROS scavenging.

Pse interferes with RANKL-induced activation of NF-κB and MAPK pathways

NF-κB and MAPK pathways are regarded as the main signaling pathways activated during osteoclastogenesis [6], and RANKL-induced ROS generation may trigger these signaling events. In order to further explore whether Pse blocked ROS activated osteoclastogenesis via attenuating NF-κB and MAPK signaling, we investigated these two pathways using Western Blot and luciferase assay. For the NF-κB pathway, we analyzed the expression of IkB-α. NF-κB transcription factors are bound to IkB-α and retained in an inactive state, these are activated and released when IkB-α is degraded after stimulation with RANKL [40]. Within 60 minutes of stimulation with RANKL, IkB-α degradation was significantly inhibited by Pse (Figure 5A and B), thus indicating failure to activate NF-κB signaling. Consistent with inhibition of IkB-α degradation, the results of luciferase assay showed the activation of NF-κB was significantly inhibited by treatment with Pse (Figure 5C). For the MAPK signaling pathway, as shown in Figure 5D, phosphorylation of ERK (Figure 5E), p38 (Figure 5F), and JNK (Figure 5G) relative to total ERK, total p38, and total JNK was suppressed significantly by Pse treatment in BMMs. Collectively, these data suggested Pse had an inhibitory effect on both NF-κB and MAPK activation pathways mediated by RANKL.

Pse attenuates NFATc1 activity and downstream factors

NFATc1 acts as the master transcriptional regulator of osteoclastogenesis [7]. In this study, RAW264.7 cells stably expressing an NFATc1-driven luciferase reporter gene were used to measure the NFATc1 transcriptional activity. After stimulation with RANKL, NFATc1 activity was very highly elevated (Figure 5H). In contrast, NFATc1 activity was abrogated significantly in a dose-dependent manner after pre-treatment with Pse (2.5, 5, 10 µM) (Figure 5H). NFATc1 expression was also found to be suppressed over the course of osteoclast differentiation using Western Blot assay (Figure 5I and J). In addition, our results showed that Pse abrogates the elevation of integrin αV (Figure 5K), cathepsin K (Figure 5L), and V-ATPase-d2 (Figure 5M), which are all downstream proteins needed for osteoclast formation and function. Consequently, Pse treatment strongly inhibits NFATc1 activity, thus affecting downstream protein expression.

Pse prevents OVX-induced bone loss

Our results established that Pse has inhibitory effects on osteoclast formation and function in vitro. The potential of Pse to act as a prophylactic agent to protect against osteoclast-related bone disease in vivo was further explored using an OVX-induced osteoporosis mice model. Mice were
either OVX or sham operated and were then intraperitoneally injected with either Pse at a concentration of 5 mg/kg every 2 days, or vehicle only for 6 weeks post-surgery (Figure 6A). No adverse events or fatalities were recorded after the OVX procedure and Pse administration. Furthermore, there were no observable effects of Pse on body weight in treated mice relative to non-treated mice (Figure S5A). Micro-CT confirmed that Pse prevented the extensive bone loss induced by the OVX procedure in mouse femurs (Figure 6B). Quantitative analysis of bone parameters also confirmed increased BV/TV, Tb.N and Conn.Dn in Pse treated group relative to the OVX mice without Pse treatment (Figure 6C-E). However, Tb.Th remained unchanged in this study (Figure 6F). Consistently, histological examination showed that Pse reduced the extent of bone loss induced by OVX (Figure 6G). Quantification of H&E staining demonstrated that the bone volume and bone surface were both well maintained in Pse treated group compared with non-Pse treated OVX mice (Figure 6H and I). Cortical bone related parameters, including cortical thickness (Ct.Th), total cross-sectional area inside the periosteal envelope (Tt.Ar), cortical bone area (Ct.Ar), and cortical area fraction (Ct.Ar/Tt.Ar), were also analyzed (Figure S5B-F). Pse showed no effect on cortical bone.

**Pse reduces osteoclasts and ROS production in the OVX mouse model**

Histological staining using TRAcP was performed on femur sections to examine the number of osteoclasts in vivo. As shown in Figure 7A, the OVX procedure led to an increased number of TRAcP-positive osteoclasts, whereas Pse treatment prevented the increase of osteoclast number in vivo. This was supported by quantification of osteoclast parameters, demonstrating a reduction in the number and surface area of osteoclasts on the bone surface in Pse treated mice (Figure 7B and C). In addition, as Pse exhibited in vitro anti-oxidant activity, in vivo ROS level was also assessed in cryosections of bone tissue using DHE, a probe that detects ROS. Consistent with previous publications [41, 42], ROS fluorescence intensity was highly elevated due to OVX procedure and Pse dramatically reversed the ROS production within the bone marrow microenvironment (Figure 7 D and E). Taken together, these data indicated that Pse prevented OVX-induced bone loss in vivo by scavenging ROS thus inhibiting osteoclast activity.

**Discussion**

Osteoporosis is a skeletal disease which is characterized by low bone mass, leading to reduced bone strength and susceptibility to fracture. It is more frequently diagnosed in the postmenopausal population majorly due to excessive osteoclast activity. Therefore, osteoclasts remain as the major target in dealing with osteoporosis. Current clinically available therapies for osteoporosis such as estrogen replacement, bisphosphonates, and denosumab are effective but have limitations and side-effects including increased risk of breast cancer, osteonecrosis of the jaw, and atypical femur fracture [43, 44]. A search for novel alternative drugs is always required for the improved treatment of osteoporosis. In the present study, we elucidated for the first time that Pse inhibited osteoclastogenesis in vitro and prevented the development of OVX-induced osteoporosis in vivo via suppressing ROS level.

Firstly, osteoclastogenesis assay and hydroxyapatite resorption assay in vitro, showed Pse as a potentially novel therapy for osteoclast-related bone disease. Further, we investigated the mechanisms underlying this inhibitory effect on osteoclast formation and function, especially regarding the intracellular ROS level, NF-κB pathway, MAPK pathway, and NFATc1.
Upon stimulation with RANKL, intracellular ROS level was hugely suppressed by Pse treatment, which was accompanied by the reduced activation of NF-κB and MAPKs, leading to the subsequent attenuation of NFATc1. The level of intracellular ROS depends on the balance between the rate of production and the rate of scavenging. ROS are generated during osteoclastogenesis through a signaling cascade including TRAF6, Rac1, and Nox1 [9]. Nox1-mediated ROS production was found to regulate RANKL-induced signaling and is required for osteoclastogenesis [9, 39]. Therefore, we hypothesized that the down-regulated ROS signaling might be partly due to the inhibition of Nox1. Indeed, Pse effectively attenuated Nox1 expression via the suppression of GTP-Rac1. To scavenge oxidative stress and maintain redox homeostasis, a wide range of antioxidant enzymes are induced. Several ROS scavengers were determined to be upregulated by Pse in this study, such as HO-1, catalase, and GSR. HO-1 induction may act as a defense mechanism to catalyze heme liberated by oxidants [45]. Catalase plays a key role in converting hydrogen peroxide into water and oxygen [46]. GSR converts glutathione disulphide back to glutathione in an NADPH-consuming process and GSR inhibitor was also found to induce the activation of the NF-κB pathway [47]. The mechanisms behind the upregulation of antioxidant enzymes still remain unclear. Nuclear factor-erythroid 2 related factor 2 (Nrf2) is regarded as an important redox-sensitive transcription factor that positively regulates antioxidant enzymes [12, 13]. RANKL stimulation attenuated the gene expression of Nrf2 to favour ROS signalling, whereas Pse treatment recovered and upregulated Nrf2 expression dose dependently (Figure S4), suggesting that Pse may upregulate antioxidant enzymes at least in part via augmenting Nrf2. Taken together, Pse attenuates the ROS level by suppressing ROS production as well as enhancing ROS scavenging.

Accumulating evidence suggests that RANKL-induced ROS signaling regulates MAPK and NF-κB activation [9, 18, 48-50]. NF-κB signaling serves a crucial role and appears to be the first event in early osteoclast development from precursors, followed by c-Fos and NFATc1 activation [7]. Loss of NF-κB signaling in mice leads to an osteopetrotic bone phenotype due to a defect of osteoclastogenesis [51]. Tumor necrosis factor α (TNFα)-induced NF-κB activation is redox-dependently regulated through the dynein light chain LC8 [48]. ROS is able to oxidize LC8 to a homodimer linked by a disulphide bond between the Cys2 residues of each subunit, which promotes its dissociation from IκBα and thereby allows IκBα’s phosphorylation and degradation by IκB kinase (IKK), thus releasing NF-κB dimers to translocate to nucleus [48]. In our study, Pse treatment effectively suppressed RANKL-induced IκB-α degradation, as demonstrated by a higher expression level of IκB-α in the Pse treated group, suggesting the involvement of IκB-dependent inactivation of NF-κB in the inhibitory effect of Pse on osteoclast formation. Furthermore, luciferase assay results consistently supported the inhibitory effect of Pse on NF-κB transcriptional activation.

The MAPK pathways, including three major MAPK family members (ERKs, JNKs, and p38), are also important signaling events involved in osteoclast differentiation stimulated by RANKL [6]. ERK is crucial for the survival of osteoclasts [52, 53]. Similarly, JNK and p38 are also phosphorylated during osteoclastogenesis in response to RANKL stimulation [53, 54]. MAPKs are activated by MAPK kinases through phosphorylation of tyrosine and threonine and inactivated by MAPK phosphatases (MKPs) through dephosphorylation [55]. ROS may act as a physiologic second messenger and oxidize tyrosine phosphatases, thus inhibiting MKPs and subsequently activating MAPKs [9, 56]. In the present study, the Western Blot results showed
that Pse comprehensively attenuated the phosphorylation of ERK, JNK, and p38 thus achieving its inhibitory effects. Thus, ROS is suggested to incorporate into the activation of NF-κB and MAPKs during osteoclastogenesis.

NFATc1 is well-known as a master transcriptional regulator of terminal osteoclast differentiation, and its initiation is regulated in an auto-amplification loop to maintain robust expression by binding to its own promoter [8]. NFATc1 modulates the expression of osteoclast downstream gene expression, and NFATc1-deficiency results in inhibition of osteoclastogenesis in vitro and osteopetrosis in vivo [57]. Here, our data implicated that the expression level and transcriptional activity of NFATc1 were reduced by Pse following RANKL stimulation. The mechanism behind the reduction of NFATc1 still remains unclear. It could result from the suppression of upstream NF-κB and MAPK signaling or a direct intervention of NFATc1 activation. We further demonstrated that Pse suppressed the expression of osteoclast-specific genes, including Ctsk, Acp5, Atp6v0d2, and Mmp9, which are regulated by NFATc1 directly or indirectly [58, 59], and participate in osteoclast formation and their bone resorptive function. C-Fos, which cooperates with NFATc1 in the context of activator protein 1 (AP-1) and contributes to osteoclast differentiation [60], was also found to be inhibited by Pse treatment at mRNA expression level.

Based on these convincing in vitro results, an OVX mouse model was further used to evaluate whether Pse has therapeutic effects in vivo through its antioxidant activity. It is interesting to note that oxidative stress status has a negative correlation with osteoporotic status. OVX rats were found to have higher oxidative stress in the femurs accompanied by a decreased activity of antioxidant systems compared to sham-operated control rats [41, 61]. Furthermore, Altindag et al. found that the oxidative stress index values and total plasma oxidant status in osteoporotic postmenopausal women was higher than that in the healthy group [42]. The development of osteoporosis is at least partly due to the imbalance between antioxidant defenses and oxidative stress. This compelling evidence provides a new insight into a potential approach for the treatment of postmenopausal osteoporosis via suppressing oxidative stress.

Our results indicated that Pse exhibited a significant protective effect on OVX-induced bone loss in mice by scavenging ROS. A previous study on ROS detection in bone used direct staining on histological sections to assess ROS levels [16]. However, the stability of ROS levels is likely to be highly variable using this method due to the lengthy tissue fixation and processing times. In this study, a ROS probe was intravenously injected 24h prior to euthanasia, which allowed DHE to be distributed to cells and tissues via the circulation. DHE is a probe that is particularly sensitive to superoxide anion levels and it was previously reported as an in vivo marker for ROS [37]. The imaging of bone tissue remains challenging because of its calcified nature. Herein, a protocol of mild fixation, decalcification, and cryo-sectioning was used to process the bone samples, which was able to effectively preserve cellular morphology and tissue architecture [38]. To our knowledge, this is the first time that DHE was used as a ROS probe to detect ROS in vivo using histological sections in an OVX model. Our data showed that ROS levels within bone marrow were dramatically suppressed in the Pse treated group, which was accompanied by a reduced number of TRAcP-positive osteoclasts. The prevention of bone loss by Pse was thought to be due to its suppression of oxidative stress and subsequent compromised osteoclast formation and function. However, this probe is not cell or tissue-specific, this data only indicated the total ROS level in bone marrow microenvironment, osteoclast-specific ROS in this study still remains to be further investigated.
In summary, this study has demonstrated for the first time that Pse can suppress intracellular ROS level by inhibiting RANKL-induced ROS production and enhancing expression of antioxidant enzymes, which attenuates the activation of MAPK and NF-κB pathways, subsequently leading to attenuation of NFATc1 as well as its downstream proteins (Figure 8). These signaling events contribute to decreased osteoclast formation and bone resorptive function in vitro. Additionally, Pse was also found to prevent estrogen deficiency-induced osteoporosis in vivo via suppressing oxidative stress in the bone marrow microenvironment. Therefore, Pse may serve as a novel candidate or an alternative therapeutic treatment for osteoclast-related bone disease such as osteoporosis.

Abbreviations

Acp5, acid phosphatase 5, tartrate resistant; Atp6v0d2, ATPase H+ Transporting V0 Subunit D2; BMMs: bone marrow macrophages; BV/TV: bone volume per tissue volume; c-fos, Proto-oncogene C-Fos; Cisk, cathepsin K; Conn.Dn: connectivity density; DAPI: 4,6-diamidino-2-phenylindole; DCF: 2',7'-dichlorofluorescein; DHE: dihydroethidium; FBS: fetal bovine serum; GCS: γ-glutamylcysteine synthetase; GSR: glutathione reductase; GTP, Guanosine 5'-triphosphate; H2DCFDA: 2',7'-dichlorodihydrofluorescein diacetate; HO-1: heme oxygenase-1; IKK: IkB kinase; MAPKs: mitogen-activated protein kinases; M-CSF: macrophage-colony stimulating factor; Mmp9, matrix metallopeptidase 9; NADPH: nicotinamide adenine dinucleotide phosphate; NAD(P)H: quinone reductase (NQO1); NFATc1: nuclear factor of activated T cells 1; NF-kB: nuclear factor-kB; NOX: NADPH oxidase; PBS: phosphate buffered saline; PCR, polymerase chain reaction; Pse: Pseurotin A; PVP: polyvinylpyrrolidone; OVX: ovariectomized; RANKL, receptor activator of nuclear factor-kB ligand; Rac1, Ras-related C3 botulinum toxin substrate 1; ROS: reactive oxygen species; Tb.N: trabecular number; TNF: tumor necrosis factor; Tb.Th: trabecular thickness; TRAcP: tartrate resistant acid phosphatase; TRAF6: TNF receptor-associated factor 6;

Acknowledgements

This study was supported by grants from the Australian Health and Medical Research Council (NHMRC, No. 1107828, 1027932). This study was also supported by the National Nature Science Fund of China (81702143). Kai Chen is supported by Australian Government Research Training Program Scholarship. We acknowledge the facilities and technical assistance of the Centre for Microscopy, Characterization & Analysis, the University of Western Australia.

Contributions

Kai Chen, Yu Yuan, Jianbo He, Chao Wang, and Qiang Guo performed cell culture, qPCR and signaling studies; Pengcheng Qiu, Lin Zheng, and Xianfeng Lin performed animal experiments; Kai Chen, Jacob Kenny, and Qian Liu performed histological analyses; Kai Chen, Junhao Chen, and Jianbo He prepared the figures; Kai Chen, Junhao Chen, Jennifer Tickner wrote the manuscript; Jingmin Zhao designed animal experiments; Kai Chen, Jiake Xu, and Jianbo He revised the manuscript; Jiake Xu, Xianfeng Lin, and Shunwu Fan designed and supervised the overall study and revised the manuscript. All of the authors declared that they have no conflicts of interest.
Competing interest

The authors have declared that no competing interest exists.

References:

Figure 1. Pse suppresses RANKL-induced osteoclastogenesis in vitro. (A) The chemical structure and formula of Pse. (B) Representative images of TRAcP staining showing that Pse inhibited osteoclastogenesis dose-dependently. BMMs were stimulated with RANKL for 5 days in the absence or presence of indicated concentrations of Pse. (C) Quantification of TRAcP-positive multinucleated cells (nuclei >3) (n=3 per group). (D) Effects of Pse on BMM viability after 48 h treatment as measured by MTS assay (n=3 per group). (E) Representative images of TRAcP staining showing BMMs treated with Pse for the indicated days during osteoclastogenesis. (F) Quantification of TRAcP-positive multinucleated cells treated with Pse in different time periods (n=3 per group). All bar graphs are presented as mean ± SD. *p<0.05, **p<0.01 compared with control group (without Pse treatment). Scale bar = 200 µM. BMMs, bone marrow macrophages; OD, optical density; Pse, Pseurotin A; RANKL, receptor activator of nuclear factor-κB ligand; TRAcP, tartrate-resistant acid phosphatase.
Figure 2. Pse affects podosome belts formation and inhibits osteoclast-specific genes expression. (A) Representative images showing the impaired podosome belts formation in osteoclasts treated with Pse. Vinculin (green), F-actin (red) and nuclei (blue) staining of osteoclasts on glass coverslip and observed by confocal microscopy. Overlapping expression is shown in yellow. (B) Quantification of the nuclei number per osteoclast (n=16 per group). (C) Quantification of the relative area of osteoclast (n=16 per group). (D-I) qPCR analysis of osteoclast-specific genes expression of c-fos, Nfatc1, Ctsk, Acp5, Atp6v0d2, and Mmp9 relative to Hprt1 and Hmbs in BMMs stimulated with RANKL for 5 days in the presence of 10 µM Pse (n=3 per group). All bar graphs are presented as mean ± SD. **p<0.01 compared with the control group (treated with RANKL but without Pse). Scale bar = 200 µM. Acp5, acid phosphatase 5, tartrate resistant; Atp6v0d2, ATPase H+ Transporting V0 Subunit D2; BMMs, bone marrow macrophages; c-fos, Proto-oncogene C-Fos; Ctsk, cathepsin K; Mmp9, matrix metallopeptidase 9; Nfatc1, nuclear factor of activated T cells 1; PCR, polymerase chain reaction; Pse, Pseurotin A; RANKL, receptor activator of nuclear factor-κB ligand; TRAcP, tartrate-resistant acid phosphatase
Figure 3. Pse inhibits osteoclast resorptive function. (A) Representative images showing the osteoclastogenesis and hydroxyapatite resorption in each group. Osteoclasts were seeded in hydroxyapatite-coated plates and treated by RANKL with or without Pse. Half of the wells for each group were stained by TRAcP or washed with 10% bleach solution. (B-C) Quantification of resorbed hydroxyapatite area per well and resorbed area per osteoclast in each group (n=3 per group). All bar graphs are presented as mean ± SD. *p<0.05, compared with control. Scale bar = 200 μM. Pse, Pseurotin A; RANKL, receptor activator of nuclear factor-κB ligand; TRAcP, tartrate-resistant acid phosphatase.
Figure 4. Pse attenuates RANKL-induced ROS generation in vitro. (A) Representative confocal images of RANKL-induced BMMs ROS generation with or without pre-treatment of Pse. Intracellular ROS generation reacted with the cell permeant, oxidation-sensitive dye H2DCFHDA and was detected in the form of highly fluorescent DCF. The lower panel is a merge of DCF fluorescence and confocal digital interference contrast (DIC) images. (B) Quantification of DCF fluorescence intensity averaged on cells of each well (n=3 per group). (C) Quantification of the number of ROS-positive cells per field (n=3). (D) Representative Western Blot images of the effects of Pse on GTP-Rac1. BMMs were pretreated with Pse at indicated concentrations and were then stimulated with RANKL for 0, 5, and 15 min. Cell lysates were collected and incubated with GST-Human PAK1-PBD fusion protein that binds to GTP-bound Rac1. Rac1 activation levels were then detected with anti-Rac1 antibody. (E) Quantification of the ratios of band intensity of GTP-Rac1 relative to Rac1 (n=3 per group). (F) Representative Western Blot images of the effects of Pse on TRAF6 and Nox1 expression. BMMs were stimulated with RANKL (50 ng/mL) in the absence or presence of Pse (2.5, 5, 10 μM) for 2 days before protein collection for Western Blot. (G and H) Quantification of the ratios of band intensity of TRAF6 and Nox1 relative to β-actin (n=3 per group). (I) Representative Western Blot images of the effects of Pse on expression of antioxidant enzymes, including HO-1, Catalase, and GSR. (J-K) Quantification of the ratios of band intensity of HO-1, Catalase, and GSR relative to β-actin (n=3 per group). All bar graphs are presented as mean ± SD. *p<0.01, **p<0.01 relative to RANKL-induced control group. Scale bar = 200 μm. BMMs, bone marrow macrophages; DCF, 2',7'-dichlorofluorescein; GSR, glutathione reductase; GTP, Guanosine-5'-triphosphate; H2DCFDA, 2',7'-dichlorodihydrofluorescein diacetate; HO-1, heme oxygenase-1; NOX, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase; Pse, Pseurotin A; Rac1, Ras-related C3 botulinum toxin substrate 1; RANKL, receptor activator of nuclear factor-κB ligand; ROS, reactive oxygen species; TRAF6, TNF receptor-associated factor 6.
Figure 5. Pse suppresses osteoclast differentiation by inhibiting the activation of NF-κB pathway, MAPK pathway, and NFATc1 signaling. (A) Representative Western Blot images of the effects of Pse on IκBα degradation induced by RANKL. (B) Quantification of the ratios of band intensity of IκBα relative to β-actin (n=3 per group). (C) NF-κB luciferase assay showing that Pse inhibited NF-κB transcriptional activity dose-dependently (n=3 per group). (D) Representative Western Blot images of the effects of Pse on MAPKs pathway, including p-ERK, p-P38, and p-JNK. BMMs were pretreated with 10 μM Pse for 2 h prior to the addition of RANKL at the indicated time points and the indicated proteins were determined. (E-G)
Quantification of the ratios of band intensity relative to ERK, P38, and JNK were analyzed (n=3 per group). (H) NFATc1 luciferase assay showing Pse significantly inhibited NFATc1 transcriptional activity (n=3 per group). (I) Representative Western Blot images of the expression levels of NFATc1 and osteoclast-related proteins including Integrin αV, Cathepsin K, and V-ATPase-d2 during osteoclastogenesis. BMMs were stimulated with RANKL in the absence or presence of 10 µM Pse for 0, 1, 3, and 5 days before protein collection for Western Blot. (J-M) Quantification of the ratios of band intensity of NFATc1, Integrin αV, Cathepsin K, and V-ATPase-d2 relative to β-actin (n=3 per group). All bar graphs are presented as mean ± SD. *P<0.05, **P<0.01 relative to RANKL-induced control group at the same time point. BMMs, bone marrow macrophages, MAPKs, mitogen-activated protein kinases; NFATc1, nuclear factor of activated T cells 1; NF-κB, nuclear factor-κB; Pse, Pseurotin A
Figure 6. Pse treatment prevents ovariectomized (OVX)-induced bone loss in vivo. (A) Schematic illustration of the establishment of OVX mouse model and the experimental design to
evaluate Pse’s therapeutic effects. (B) Representative μCT images showing that the bone loss was prevented by Pse administration. (C-F) Quantitative analyses of parameters regarding bone microstructure, including BV/TV, Tb.N, Conn.Dn, and Tb.Th (N=6 per group). (G) Representative images of HE staining of decalcified bone sections. (H-I) Quantitative analyses of BV/TV and BS in tissue sections (n=4 per group). All bar graphs are presented as mean ± SD. **P<0.01 relative to the OVX group. BS, bone surface; BV/TV, bone volume per tissue volume; Conn.Dn, connectivity density; HE, hematoxylin and eosin; NS, non-significant; Pse, Pseurotin A; TB, trabecular bone; Tb.N, trabecular number; Tb.Th, trabecular thickness
Figure 7. Pse treatment reduces osteoclasts and ROS production in OVX mice. (A) Representative images of TRAcP staining of decalcified bone sections. (B-C) Quantitative analyses of N.Oc/BS and Oc.S/BS (n=4 per group). (D) Representative images of bone cryosections showing ROS fluorescence in different groups. (E) Quantitative analyses of ROS fluorescence intensity relative to sham group (n=5 per group). All bar graphs are presented as mean ± SD. **P<0.01 relative to the OVX group. BM, bone marrow; DAPI, 4,6-diamidino-2-phenylindole; DHE, dihydroethidium; GP, growth plate; ROS, reactive oxygen species; N.Oc/BS, osteoclast number/bone surface; Oc.S/BS, osteoclast surface/bone surface; TB, trabecular bone; TRAcP, tartrate resistant acid phosphatase
Figure 8. A proposed scheme for the inhibition of Pse on osteoclastogenesis. Upon RANKL binding to RANK, both NF-κB and MAPKs pathways are activated, leading to the amplification of NFATc1. Several osteoclast-specific genes such as Ctsk, Acp5, Atp6v0d2, and Mmp9 are upregulated as a result. These signaling events are mediated by RANKL-induced ROS signaling. Our results demonstrated for the first time that Pse inhibits osteoclastogenesis via suppressing ROS level by inhibiting RANKL-induced ROS production and enhancing expression of antioxidant enzymes. Acp5, acid phosphatase 5, tartrate resistant; AP-1, activator protein 1; Atp6v0d2, ATPase H+ Transporting V0 Subunit D2; NFATc1, nuclear factor of activated T cells 1; c-fos, Proto-oncogene C-Fos; Ctsk, cathepsin K; Mmp9, matrix metallopeptidase 9; NOX, nicotinamide adenine dinucleotide phosphate oxidase; Pse, Pseurotin A; Rac1, Ras-related C3 botulinum toxin substrate 1; RANKL, receptor activator of nuclear factor-κB (NF-κB) ligand; ROS, reactive oxygen species.
**Graphical Abstract**: By suppressing reactive oxygen species (ROS), Pseurotin A (Pse) inhibits RANKL-induced osteoclastogenesis in vitro and prevents ovariectomy (OVX)-induced bone loss in vivo.
Supplementary Results

Figure S1. Flow cytometric analysis for bone marrow-derived macrophages. (A) CD11b expression in isotype control stained cells (grey) and APC conjugated CD11b stained cells (red) within single cell population. (B) The percentage of CD11b+ cells were determined in triplicate.

Figure S2. Pse showed no effect on osteoclast apoptosis. (A) After mature osteoclasts induced by RANKL, different concentrations of Pse (0, 5, 10 μM) were used to treat the cells for additional 2 days. As a positive control for apoptosis, DNase I treatment (3,000 U/mL, 30 min) was included. Apoptotic osteoclasts were then assessed by TUNEL assay (green). Nuclei were visualized by DAPI staining. The TUNEL-positive apoptotic nuclei are indicated by white arrows. (B) The quantification of the percentage of TUNEL-positive nuclei in each group (n=5 per group). All bar graphs are presented as mean ± SD. **p<0.01 compared with the group without Pse and DNase I treatment. Scale bar=100 μm. DAPI, 4,6-diamidino-2-phenylindole; Pse, Pseurotin A; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labelling; OC, osteoclast
Figure S3. Confocal images of podosome belts of osteoclasts. (A) High magnification confocal images showing podosome belts formation in osteoclasts treated with or without Pse. (B) Fluorescence intensity profile through podosome belts (indicated by the white arrow in A). DAPI, 4,6-diamidino-2-phenylindole; Pse, Pseudoth A
Figure S4. ROS-related genes expression in RANKL-stimulated BMMs. The expressions of Nox1 (A), Nrf2 (B), Nrf2/Keap1 (C), HMOX1 (D), CAT (E), and GCLC (F) were examined by qPCR after 2-day RANKL stimulation in the absence or presence of Pse (5, 10 μM). Gene expression was calibrated using the Hprt1 housekeeping gene. **p<0.01 compared with the group with only RANKL treatment. CAT, catalase; GCLC, gamma-glutamylcysteine synthetase; HMOX1, heme oxygenase 1; Hprt1, hypoxanthine phosphoribosyltransferase 1; Keap1, kelch like ech associated protein 1; Nox1, nicotinamide adenine dinucleotide phosphate oxidase 1; Nrf2, nuclear factor-erythroid 2 related factor 2; Pse, Pseurotin A; RANKL, receptor activator of nuclear factor-κB (NF-κB) ligand
Figure S5. Body weights and cortical bone parameters of all mice in each group. (A) Body weights of all mice recorded at indicated time points. (B) Representative μCT images of femur cortical bone in each group. (C-F) Quantitative analyses of cortical bone related parameters, including cortical thickness (Ct.Th), total cross-sectional area inside the periosteal envelope (Tt.Ar), cortical bone area (Ct.Ar), and cortical area fraction (Ct.Ar/Tt.Ar) (N=6 per group). All bar graphs are presented as mean ± SD. *P<0.05, **P<0.01 relative to the OVX group. OVX, ovariectomized; Pse, Pseurotin A; ns, non-significant.
Supplementary Methods

Flow cytometric analysis for macrophage marker.
Bone marrow was flushed from the long bone (femur and tibia) of mice and then cultured in complete αMEM for 24h. Non-adherent cells were then collected and cultured in complete αMEM containing M-CSF (50 ng/mL) for 3 days culture. The attached cells were used for flow cytometric analysis. To investigate the purity of bone marrow macrophages (BMMs), cell suspension (5 x 10^5 cells) were incubated with APC conjugated monoclonal antibody for mouse CD11b (Thermo Fisher Scientific, Scoresby, VIC, Australia) or isotype-matched control IgGs for 30 min on ice. After washing 3 times, cells were subjected to flow cytometric analysis using FACSCantoII (BD Biosciences, New Jersey, USA). Data were processed using FlowJo software (FlowJo LLC, Ashland, Oregon, USA).

TUNEL assay
TUNEL assays were performed using an In Situ Cell Death Detection kit (Sigma-Aldrich, Sydney, NSW, Australia). 6 x 10^3 BMMs were seeded onto coverslips in 96-well plates and were induced into osteoclasts. To determine whether Pse can induce osteoclast apoptosis,
cells were cultured with M-CSF and RANKL for further 2 days after mature osteoclasts formation. Cells were treated with different concentrations of Pse (0, 5, 10 μM). DNase I (3,000 U/mL, 30 min) treated cells were used as positive control. Cells were fixed with 4% formaldehyde and permeabilized with 0.1% Triton X-100 for 15 minutes. Cells were then processed following the manufacturer’s protocol in order to label fragmented DNA. Nuclei were stained with DAPI. The percentage of nuclei was used to evaluate Pse’s effect on apoptosis.

Osteoblast differentiation
To determine whether Pse has effects on osteoblast, MC3T3-E1 cells (ATCC, Manassas, Virginia, USA) were cultured with α-MEM, 10% FBS, and 1% penicillin-streptomycin at 37°C in a humidified atmosphere of 5% CO₂. To induce osteogenic differentiation, cells (1.0 x 10⁴/well) were seeded in 48-well plates overnight and then changed into osteogenic medium (10 mM β-glycerophosphate and 50 μg/mL ascorbic acid) with different concentrations of Pse (5, 10 μM). BMP-2 (50 ng/mL) treatment was used as positive control; Group without Pse and BMP-2 was negative control. Medium was changed every 3 days. After incubation for 0, 7, and 14 days, cells in each group were fixed in 4% paraformaldehyde for 10 min, washed with PBS for 3 times, and stained by BCIP/NBT liquid substrate system (Sigma-Aldrich, Sydney, NSW, Australia) for alkaline phosphatase (ALP) at 37°C for 30 min.

**Supplementary Table 1. Primers Sequences**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward (5'-3')</th>
<th>Reverse (5'-3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpl</td>
<td>CAGGCCGCTTCATAGCA</td>
<td>AATTGACGGTCGATCTGC</td>
</tr>
<tr>
<td>Bglap</td>
<td>GCGCTCGTCGTCGACTCT</td>
<td>ACCCTATGGCCCTGCTGTT</td>
</tr>
<tr>
<td>Tnfrsf11b</td>
<td>GCCACGCAAGTGTGAAT</td>
<td>TTTGTCACGGCCTGCTGTT</td>
</tr>
<tr>
<td>Sp7/Osx</td>
<td>GTCTCTCTCTGGAAAGAAGAAGAA</td>
<td>GGGCTGAAAGGTCAGGATAT</td>
</tr>
<tr>
<td>Actb</td>
<td>CACCCGCGAGCAGCTTCT</td>
<td>CAACATCAACCCCTGCTGCT</td>
</tr>
<tr>
<td>Nox1</td>
<td>CAGTTTTCGTCGGCAAAGGACC</td>
<td>CCAACCAGAAACCAAGCAAACAA</td>
</tr>
<tr>
<td>Nrf2</td>
<td>TCTCCTGCTGAAAGAAGAAGA</td>
<td>AATGTGCTGCTGCTGCTTTA</td>
</tr>
<tr>
<td>CAT</td>
<td>CTCGACAGACCTGTACATG</td>
<td>GACCGCGCTAGATGATT</td>
</tr>
<tr>
<td>HMOX1</td>
<td>GAGCAGAAACAGCTGAACCT</td>
<td>AAATCTGCGGGGTGATGTC</td>
</tr>
<tr>
<td>Keap1</td>
<td>TGGGCTGCTGCTGCTGCTG</td>
<td>GGTCGGGTGTCCTGCTG</td>
</tr>
<tr>
<td>GCLC</td>
<td>GGGTGACGAGGTGGAGTA</td>
<td>GTGTCGGGTGTCCTGCTCC</td>
</tr>
</tbody>
</table>